

CLAIMS

1. ^{A molecule comprising} ~~The use of a cC1qR binding domain~~ ^{useful} in the manufacture of a medicament to effect CUB domain functionality.

2. ^{molecule} ~~The use of a cC1qR binding domain~~ ^{cC1qR} according to claim 1, the ^{binding} domain forming part of a C1q receptor.

3. ^{molecule} ~~The use of a cC1qR binding domain~~ ^{claim 1} according to ~~either one of claims 1 or 2~~, the cC1qR binding domain being recombinant.

4. ^{A molecule comprising} ~~The use of an inhibitor of the cC1qR binding domain~~ ^{useful} in the manufacture of a medicament to inhibit CUB functionality.

5. ^{molecule} ~~The use of an inhibitor of the cC1qR binding domain~~ ^{wherein} according to claim 4, the inhibitor ^{comprises} ~~comprising~~ a cC1qR binding domain.

6. ^{molecule according to claim 4, wherein the inhibitor of the cC1qR binding domain is useful} ~~The use of an inhibitor of the cC1qR binding domain according to either one of claims 4 or 5~~ in the manufacture of a medicament for the treatment of complement activation involved in the initiation and maintenance of inflammation.

7. ^{molecule} ~~The use of an inhibitor of the cC1qR binding domain~~ ^{wherein the inhibitor of the cC1qR binding domain is useful} according to claim 6, in the manufacture of a medicament for the treatment of myocardial infarction, brain ischemia (stroke), gut ischemia, rheumatoid arthritis, systemic lupus erythematosus, burns, or immune complex nephritis.

- 15 -

A

molecule according to claim 4, wherein the inhibitor of the cClqR binding domain is useful

8. ~~The use of an inhibitor of the cClqR binding domain according to either~~
~~one of claims 4 or 5~~ in the manufacture of a medicament for the treatment of amyloid
plaques in Alzheimers disease.

A

A molecule comprising a cClqR binding domain

9. ~~The use of a cClqR binding domain or inhibitor thereof according to any~~
~~one of the preceding claims~~, the cClqR binding domain having the sequence of any one
of SEQ ID NOs: 1-3 or a partially modified form thereof.

A

pub B2 10. A method of treatment of the human or animal body comprising the use of
a cClqR binding domain or an inhibitor thereof ~~according to any one of the preceding~~
~~claims.~~

Add B3